{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:50Z","timestamp":1787113670338,"version":"build-2736575974"},"reference-count":49,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Breast Cancer Research Institute, Ireland","award":["2026"],"award-info":[{"award-number":["2026"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>MicroRNAs (miRNAs) have emerged as promising biomarkers for treatment response prediction in breast cancer. However, the role of circulating and tumour-derived miRNAs in predicting pathological complete response (pCR) following neoadjuvant therapy in HER2-positive (HER2+) breast cancer remains incompletely defined. To systematically evaluate the association between miRNA expression profiles and pCR in HER2+ breast cancer undergoing neoadjuvant systemic therapy, including chemotherapy with HER2-targeted agents. A systematic review of PUBMED, EMBASE, SCOPUS, and WEB OF SCIENCE databases was performed according to PRISMA guidelines. Studies evaluating circulating or tumour-derived miRNAs associated with pCR following neoadjuvant therapy in HER2+ breast cancer were included. Methodological quality was assessed using the QUIPS tool. Nine studies involving 937 HER2+ breast cancer patients were included. Overall, 39 unique miRNAs and four circulating miRNA signatures were associated with pCR outcomes. Seven studies evaluated circulating miRNAs, while two assessed tumour-derived miRNAs. The increased expression of six circulating miRNAs, four circulating signatures, and seventeen tumour-derived miRNAs was associated with pCR. Conversely, the increased expression of eleven circulating miRNAs and five tumour-derived miRNAs was associated with residual disease and non-pCR. MiR-210 was the only miRNA associated with response across more than one study, with an increased expression associated with residual disease in both circulating and tumour-derived analyses. Several circulating and tumour-derived miRNAs demonstrate potential as predictive biomarkers of pCR following HER2-targeted neoadjuvant therapy. However, substantial heterogeneity and limited validation currently restrict clinical implementation. Future prospective multicentre studies using standardised methodologies are required to clarify the role of miRNA profiling in personalised treatment strategies for HER2+ breast cancer.<\/jats:p>","DOI":"10.3390\/ijms27167345","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:42:17Z","timestamp":1786974137000},"page":"7345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating and Tissue MicroRNA Profiles Associated with Pathological Complete Response in HER2+ Breast Cancer: A Systematic Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-5291","authenticated-orcid":false,"given":"Luis","family":"Bouz Mkabaah","sequence":"first","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darragh T.","family":"McGovern","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1627-4297","authenticated-orcid":false,"given":"Eoin P.","family":"Kerin","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-9205","authenticated-orcid":false,"given":"Vinitha","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife J.","family":"Lowery","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kerin","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref_1","first-page":"439","article-title":"Breast cancer statistics, 2017, racial disparity in mortality by state","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102527","DOI":"10.1016\/j.ctrv.2023.102527","article-title":"Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review","volume":"115","author":"Bartsch","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: Advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/bjs\/znab137","article-title":"Management of the axilla after neoadjuvant chemotherapy in breast cancer patients","volume":"108","author":"Boland","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP","volume":"41","author":"Litton","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_10","first-page":"64","article-title":"MicroRNAs as key regulators of cancer drug resistance: Insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy","volume":"8","author":"Attathikhun","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"de Miranda, F.S., Slaibi-Filho, J., Calasans Dos Santos, G., Carmo, N.T., Kaneto, C.M., Borin, T.F., Luiz, W.B., and Gastalho Campos, L.C. (2024). MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer. Front. Mol. Biosci., 11.","DOI":"10.3389\/fmolb.2024.1337706"},{"key":"ref_12","first-page":"11782234221086684","article-title":"Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer\u2014A Systematic Review","volume":"16","author":"Davey","year":"2022","journal-title":"Breast Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1479-5876-10-42","article-title":"De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer","volume":"10","author":"Wu","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/cncr.26565","article-title":"Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients","volume":"118","author":"Jung","year":"2012","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37269","DOI":"10.18632\/oncotarget.5495","article-title":"MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients","volume":"6","author":"Bottai","year":"2015","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3892\/ol.2017.5628","article-title":"Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"13","author":"Ohzawa","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stevic, I., M\u00fcller, V., Weber, K., Fasching, P.A., Karn, T., Marm\u00e9, F., Schem, C., Stickeler, E., Denkert, C., and van Mackelenbergh, M. (2018). Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med., 16.","DOI":"10.1186\/s12916-018-1163-y"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-18-2507","article-title":"Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial","volume":"25","author":"Appierto","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Di Cosimo, S., Appierto, V., Pizzamiglio, S., Silvestri, M., Baselga, J., Piccart, M., Huober, J., Izquierdo, M., de la Pena, L., and Hilbers, F.S. (2020). Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041386"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zhang, S., Wang, Y., Wang, Y., Peng, J., Yuan, C., Zhou, L., Xu, S., Lin, Y., Du, Y., and Yang, F. (2020). Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00631"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/SLA.0000000000005613","article-title":"Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer: A Prospective, Multicenter Clinical Trial","volume":"276","author":"Davey","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1158\/0008-5472.CAN-12-2162","article-title":"Prooncogenic factors miR-23b and miR-27b are regulated by Her2\/Neu, EGF, and TNF-\u03b1 in breast cancer","volume":"73","author":"Jin","year":"2013","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00280-020-04168-z","article-title":"Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer","volume":"86","author":"Zhang","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11033-025-11314-4","article-title":"The dual role of miR-184 in cancer: A systematic review of context-dependent regulation","volume":"53","author":"Duff","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13996","DOI":"10.1038\/s41598-017-14454-1","article-title":"MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1","volume":"7","author":"Hulin","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3892\/or.2015.4049","article-title":"MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer","volume":"34","author":"Han","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/s41598-018-20680-y","article-title":"Elevated miR-301a expression indicates a poor prognosis for breast cancer patients","volume":"8","author":"Zheng","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ye, X.M., Zhu, H.Y., Bai, W.D., Wang, T., Wang, L., Chen, Y., Yang, A.G., and Jia, L.T. (2014). Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-134"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2360547","DOI":"10.1080\/01443615.2024.2360547","article-title":"The effect of miR-381 on proliferation and prognosis of breast cancer by altering CCNA2 expression","volume":"44","author":"Cao","year":"2024","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"149379","DOI":"10.1016\/j.gene.2025.149379","article-title":"The role of the NEAT1\/miR410-3p axis in the invasion of breast cancer cells","volume":"951","author":"Dogan","year":"2025","journal-title":"Gene"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"FSO693","DOI":"10.2144\/fsoa-2021-0014","article-title":"The role and underlying mechanism of miR-1299 in cancer","volume":"7","author":"Kaiyuan","year":"2021","journal-title":"Future Sci. OA"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, X., Papukashvili, D., Wang, Z., Liu, Y., Chen, X., Li, J., Li, Z., Hu, L., Li, Z., and Rcheulishvili, N. (2022). Potential utility of miRNAs for liquid biopsy in breast cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.940314"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/acs.jmedchem.5c02728","article-title":"Reversing the Hypoxic Adaptive Response in Breast Cancer Cells through Small-Molecule Inhibition of Oncogenic MicroRNA-210","volume":"69","author":"Panosetti","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Conte, L., Tumolo, M.R., de Nunzio, G., de Giorgi, U., Guarino, R., Cascio, D., and Cucci, F. (2025). The Prognostic Power of miR-21 in Breast Cancer: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199713"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.7150\/ijms.102123","article-title":"Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155","volume":"21","author":"Qian","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1055-9965.EPI-12-0173","article-title":"The oncogenic role of miR-155 in breast cancer","volume":"21","author":"Mattiske","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Neagoe, C.-X.-R., Gundershausen, M., Ionic\u0103, M., and Neagoe, O.C. (2026). MicroRNAs in Breast Cancer: Diagnostic and Prognostic Potential, Challenges, and Clinical Reliability. Biomedicines, 14.","DOI":"10.3390\/biomedicines14030502"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Abdul Manap, A.S., Wisham, A.A., Wong, F.W., Ahmad Najmi, H.R., Ng, Z.F., and Diba, R.S. (2024). Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1390704"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Komporaly, I.A., Gheorghe, A.S., Kajanto, L.A., Iov\u0103nescu, E.A., Georgescu, B., Mih\u0103il\u0103, R.I., Radu, A.M., Zob, D.L., Mihai, M.M., and Georgescu, M.T. (2025). miRNA and Its Implications in the Treatment Resistance in Breast Cancer\u2014Narrative Review of What Do We Know So Far. Non-Coding RNA, 11.","DOI":"10.3390\/ncrna11060078"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1373\/clinchem.2010.157198","article-title":"Analysis of circulating microRNA: Preanalytical and analytical challenges","volume":"57","author":"McDonald","year":"2011","journal-title":"Clin. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bouz Mkabaah, L., Kerin, E.P., Davey, M.G., Filandrianou, E., Richard, V., and KerinM, J. (2026). MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics\u2014Potential to Advance Personalised Approaches in Clinical Trials. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27093996"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1038\/s41388-017-0116-9","article-title":"Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379","volume":"37","author":"Khan","year":"2018","journal-title":"Oncogene"},{"key":"ref_46","first-page":"785","article-title":"MicroRNAs in Cancer: From Gene Expression Regulation to the Metastatic Niche Reprogramming","volume":"86","author":"Semina","year":"2021","journal-title":"Biochemistry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"116652","DOI":"10.1016\/j.taap.2023.116652","article-title":"Plasma microRNA-195, -34c, and -1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients","volume":"475","author":"Rezaei","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Peng, J., Lin, Y., Sheng, X., Yuan, C., Wang, Y., Yin, W., Zhou, L., and Lu, J. (2024). Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12500-6"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Cardinali, B., Tasso, R., Piccioli, P., Ciferri, M.C., Quarto, R., and del Mastro, L. (2022). Circulating miRNAs in Breast Cancer Diagnosis and Prognosis. Cancers, 14.","DOI":"10.3390\/cancers14092317"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:17:52Z","timestamp":1787113072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":49,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167345"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167345","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}